Among these subtypes, hormone receptor-positive and HER2-negative breast cancer (HR+/HER2-BC) is the most heterogeneous subtype and is clinically known to have a better prognosis than other molecular subtypes [4,5]. This evidence concerns the gene ERBB2 and breast cancer.